Key result
Inhibition of plasminogen activator inhibitor-1 (PAI-1) is a potential therapeutic strategy for thrombosis, vascular remodeling, renal injury, and diabetes based on preclinical studies.
Plasminogen activator inhibitor-1 (PAI-1) is the major physiological inhibitor of fibrinolysis and regulates cell migration and fibrosis. Preclinical studies using genetically altered mice and biological or small molecule inhibitors have elucidated a role for PAI-1 in the pathogenesis of thrombosis, vascular remodeling, renal injury, and initiation of diabetes. Inhibition of PAI-1 is a potential therapeutic strategy in these diseases.
No takes yet. Share an insight, caveat, or question.
Nancy J. Brown (2010) conducted a review in Thrombosis, vascular remodeling, renal injury, and diabetes. Plasminogen activator inhibitor-1 (PAI-1) inhibitors was evaluated. Inhibition of plasminogen activator inhibitor-1 (PAI-1) is a potential therapeutic strategy for thrombosis, vascular remodeling, renal injury, and diabetes based on preclinical studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: